Synthetic Peptide Representing a T-Cell Epitope of CRM197 Substitutes as Carrier Molecule in a Haemophilus Influenzae Type B (HIB) Conjugate Vaccine
The cross-reactive material (CRM197) of diphtheria toxin is considered to be advantageous as a carrier molecule in the formulation of a Haemophilus influenzae type b conjugate vaccine. In order to more precisely understand the function of the CRM197 in the vaccine, we have begun mapping the T-cell epitopes of the protein. A peptide which represents a segment of the primary sequence of CRM197 has been identified and found to stimulate diphtheria toxoid or CRM197-primed murine T-lymphocytes. In addition, the peptide is capable of priming T-cells in vivo for a subsequent in vitro T-cell response to itself or to the intact CRM197 molecule. The ability of the peptide to replace CRM197 as a carrier molecule was examined by immunizing mice with PRP, PRP-CRM197 conjugate, or PRP covalently coupled to the peptide. Antibodies to PRP were only detected in the PRP-CRM197 or PRP-peptide immunized groups. Both conjugates elicited primary and secondary antibody responses. Thus, a synthetic peptide representing a defined T-cell epitope of CRM197 has been functionally demonstrated based on its ability to act as a carrier molecule in a PRP conjugate vaccine.
KeywordsHaemophilus Influenzae Conjugate Vaccine Capsular Polysaccharide Diphtheria Toxin Carrier Molecule
Unable to display preview. Download preview PDF.
- Bixler, G.S., and Pillai, S., (1989), The cellular basis of the immune response to conjugate vaccines, In: “Contributions to Microbiology and Immunology,” J. M. Cruse ed., S. Karger, Switzerland, (in press).Google Scholar
- Chu, C. Y., Schneerson, R., Robbins, J. B., and Rastogi, S. C., (1983), Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugate, Inf. Immun., 40:245–256.Google Scholar
- Greenberg, D. P., Ward, J. I., Burkart, K., Christenson, P. D., Guravitz, L., and Marcy, S. M., (1987), Factors influencing immunogenicity and safety of two Haemophilus influenzae type b polysaccharide vaccines in children 18 and 24 months of age, Pediatr. Infect. Dis. J., 6:660–665.PubMedCrossRefGoogle Scholar